Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies
Executive Summary
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
You may also be interested in...
Tibsovo Gets A Win In AML Following Servier Takeover
Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.
Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.